Myopic maculopathy: A review

Ophthalmologica

Volumn 228, Issue 4, 2012, Pages 197-213

  Silva, Rufino ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Choroidal neovascularization; Myopic maculopathy; Pathological myopia

Indexed keywords

BEVACIZUMAB; COLLAGEN TYPE 11; COLLAGEN TYPE 2; FIBRILLIN; PLACEBO; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ANGIOCARDIOGRAPHY; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOME 12Q; DEGENERATIVE MYOPIA; DISEASE CLASSIFICATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; FLUORESCENCE ANGIOGRAPHY; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEREDITY; HIGH MYOPIA; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; LASER COAGULATION; LASER DOPPLER FLOWMETRY; LOADING DRUG DOSE; MECHANICAL STRESS; MEDICAL RECORD REVIEW; MULTICENTER STUDY (TOPIC); MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA HEMORRHAGE; RETINA MACULA DEGENERATION; RETINA MACULA TRANSLOCATION; RETINA MACULOPATHY; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; VISUAL ACUITY;

DISEASE PROGRESSION; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; MYOPIA, DEGENERATIVE; REFRACTION, OCULAR;

EID: 84867994603     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000339893     Document Type: Review

References (198)

1. Gass JDM (ed): Stereoscopic Atlas of Macular Disease. St Louis, Mosby Co, 1997.
2. Ghafour I, Allan D, Foulds W: Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1986; 67: 209-213. (Pubitemid 13114741)
3. Sperduto R, Seigel D, Roberts J, et al: Prevalence of myopia in the United States. Arch Ophthalmol 1983; 101: 405-407. (Pubitemid 13152589)
4. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, et al: Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010; 117: 1595-1611.
5. Curtin B, Karlin D: Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol 1971; 71: 42-53.
6. Soubrane G: Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008; 53: 121-138. (Pubitemid 351381556)
7. Grossniklaus H, Green W: Pathologic findings in pathologic myopia. Retina 1992; 12: 127-133.
8. Metge, P: Definitions. Vol. La myopie forte. 1994, pp 14-17.
9. Pruett R: Pathologic myopia; in Albert DM, Jakobiec JF (eds): Principles and Practice of Ophthalmology. Philadelphia, Saunders Co, 1994, pp 878-889.
10. Tokoro T: On the definition of pathologic myopia in group studies. Acta Ophthalmol Suppl 1988; 185: 107-108.
11. Ruben M, Rajpurohit P: Distribution of myopia in aphakic retinal detachments. Br J Ophthalmol 1976; 60: 517-521.
12. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL: Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 1573-1581. (Pubitemid 15197032)
13. Fried M, Siebert A, Meyer-Schwickerath G: A natural history of Fuchs' spot: a long term follow-up study. Doc Ophthalmol 1981;28: 215-221.
14. Hampton GR, Kohen D, Bird AC: Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 923-926. (Pubitemid 13004305)
15. Hotchkiss ML, Fine SL: Pathologic myopia and choroidal neovascularization. Am J Ophthalmol 1981; 91: 177-183. (Pubitemid 11184477)
16. Secretan M, Kuhn D, Soubrane G, et al: Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997; 7: 307-316. (Pubitemid 28042043)
17. Tabandeh H, Flynn HW Jr, Scott IU, Lewis ML, Rosenfeld PJ, Rodriguez F, et al: Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999; 106: 2063-2067. (Pubitemid 30194225)
18. Yoshida T, Ohno-Matsui K, Ohtake Y, Takashima T, Futagami S, Baba T, et al: Longterm visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002; 109: 712-719. (Pubitemid 34270128)
19. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al: Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003; 110: 1297-1305. (Pubitemid 36842462)
20. Shih Y, Ho T, Hsiao C, Lin LL: Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study. Br J Ophthalmol 2006; 90: 564-550.
21. Delori FC, Goger DG, Dorey CK: Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci 2001; 42: 1855-1866. (Pubitemid 32652365)
22. Ishikawa M, Miyake Y, Shiroyama N: Focal macular electroretinogram in high myopia. Nihon Ganka Gakkai Zasshi 1990; 94: 1040-1047.
23. Ushimura S, Wakabayashi K, Kawasaki K: Electro-oculographical features of high myopia. Jpn J Clin Ophthalmol 1992; 46: 449-453.
24. Mäntyjärvi M, Tuppurainen K: Colour vision and dark adaptation in high myopia without central retinal degeneration. Br J Ophthalmol 1995; 79: 105-108.
25. Harman AM, Hoskins R, Beazley LD: Experimental eye enlargement in mature animals changes the retinal pigment epithelium. Vis Neurosci 1999; 16: 619-628. (Pubitemid 29347755)
26. Kitaya N, Ishiko S, Abiko T, Mori F, Kagokawa H, Kojima M, et al: Changes in bloodretinal barrier permeability in form deprivation myopia in tree shrews. Vision Res 2000; 40: 2369-2377.
27. Yoshida A, Ishiko S, Kojima M: Inward and outward permeability of the blood-retinal barrier in experimental myopia. Graefes Arch Clin Exp Ophthalmol 1996; 234(suppl 1):S239-S242.
28. Vongphanit J, Mitchell P, Wang JJ: Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 2002; 109: 704-711. (Pubitemid 34270127)
29. McCarty CA, Livingston PM, Taylor HR: Prevalence of myopia in adults: implications for refractive surgeons. J Refract Surg 1997; 13: 229-234. (Pubitemid 27247250)
30. Fuchs A: Frequency of myopia gravis. Am J Ophthalmol 1960; 49: 1418-1419.
31. Curtin B: The prevalence of myopia; in Curtin BE (ed): The Myopias: Basic Science and Clinical Management. Philadelphia, Harper & Row, 1985, pp 39-59.
32. Green JS, Bear JC, Johnson GJ: The burden of genetically determined eye disease. Br J Ophthalmol 1986; 70: 696-699. (Pubitemid 16053215)
33. Krumpaszky HG, Ludtke R, Mickler A, Klauss V, Selbmann HK: Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern. Ophthalmologica 1999; 213: 176-182. (Pubitemid 29192934)
34. Munier A, Gunning T, Kenny D, O'Keefe M: Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol 1998; 82: 630-633. (Pubitemid 28306651)
35. Cotter SA, Varma R, Ying-Lai M, Azen SP, Klein R, Los Angeles Latino Eye Study Group: Causes of low vision and blindness in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology 2006; 113: 1574-1582. (Pubitemid 44292317)
36. Buch H, Vinding T, Nielsen NV: Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001; 108: 2347-2357. (Pubitemid 33096957)
37. Iwase A, Araie M, Tomidokoro A, Yamamoto T, Shimizu H, Kitazawa Y, et al: Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology 2006; 113: 1354-1362.
38. Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J, et al: Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006; 113: 1134. e1-e11.
39. Jacobsen N, Jensen H, Goldschmidt E: Does the level of physical activity in university students influence development and progression of myopia? A 2-year prospective cohort study. Investigative Ophthalmol Vis Sci 2008; 49: 1322-1327.
40. Lyhne N, Sjolie AK, Kyvik KO, Green A: The importance of genes and environment for ocular refraction and its determiners: a population based study among 20-45 year old twins. Br J Ophthalmol 2001; 85: 1470-1476. (Pubitemid 34032916)
41. Lin HJ, Kung YJ, Lin YJ, Sheu JJ, Chen BH, Lan YC, et al: Association of the lumican gene functional 3-UTR polymorphism with high myopia. Invest Ophthalmol Vis Sci 2010; 51: 96-102.
42. Knowlton RG, Weaver EJ, Struyk AF, Knobloch WH, King RA, Norris K, et al: Genetic linkage analysis of hereditary arthro-ophthalmopathy (Stickler syndrome) and the type II procollagen gene. Am J Hum Genet 1989; 45: 681-688. (Pubitemid 19283777)
43. Richards AJ, Yates JR, Williams R, Payne SJ, Pope FM, Scott JD, et al: A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. Hum Mol Genet 1996; 5: 1339-1343. (Pubitemid 26335853)
44. Pousi B, Hautala T, Heikkinen J, Pajunen L, Kivirikko KI, Myllyla R: Alu-Alu recombination results in a duplication of seven exons in the lysyl hydroxylase gene in a patient with the type VI variant of Ehlers-Danlos syndrome. Am J Hum Genet 1994; 55: 899-906. (Pubitemid 24334281)
45. Sertie AL, Sossi V, Camargo AA, Zatz M, Brahe C, Passos-Bueno MR: Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome). Hum Mol Genet 2000; 9: 2051-2058. (Pubitemid 30642670)
46. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352: 337-339. (Pubitemid 21912353)
47. Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E, Pereira L, et al: Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet 1995; 57: 8-21.
48. Young TL: Dissecting the genetics of human high myopia: a molecular biologic approach. Trans Am Ophthalmol Soc 2004; 102: 423-445.
49. Ashton GC: Segregation analysis of ocular refraction and myopia. Hum Hered 1985; 35: 232-239. (Pubitemid 15233442)
50. Yap M, Wu M, Liu ZM, Lee FL, Wang SH: Role of heredity in the genesis of myopia. Ophthalmic Physiol Optics J Br Coll Ophthalmic Opticians 1993; 13: 316-319. (Pubitemid 23235864)
51. Edwards MH: Effect of parental myopia on the development of myopia in Hong Kong Chinese. Ophthalmic Physiol Optics J Br Coll Ophthalmic Opticians 1998; 18: 477-483. (Pubitemid 28508708)
52. Liang CL, Yen E, Su JY, Liu C, Chang TY, Park N, et al: Impact of family history of high myopia on level and onset of myopia. Invest Ophthalmol Vis Sci 2004; 45: 3446-3452. (Pubitemid 39298561)
53. Keller JT: A comparison of the refractive status of myopic children and their parents. Am J Optometry Arch Am Acad Optometry 1973; 50: 206-211.
54. Goss DA, Jackson TW: Clinical findings before the onset of myopia in youth. 4. Parental history of myopia. Optometry Vision Sci 1996; 73: 279-282.
55. Mutti DO, Mitchell GL, Moeschberger ML, Jones LA, Zadnik K: Parental myopia, near work, school achievement, and children's refractive error. Invest Ophthalmol Vis Sci 2002; 43: 3633-3640. (Pubitemid 35470597)
56. Gwiazda J, Thorn F, Bauer J, Held R: Emmetropization and the progression of manifest refraction in children followed from infancy to puberty. Clin Vis Sci 1993; 8: 337-344. (Pubitemid 23285288)
57. Wold K: Hereditary myopia. Arch Ophthalmol 1949; 42: 225-237.
58. Hammond CJ, Snieder H, Spector TD, Gilbert CE: Factors affecting pupil size after dilatation: the Twin Eye Study. Br J Ophthalmol 2000; 84: 1173-1176.
59. Dirani M, Chamberlain M, Shekar SN, Islam AF, Garoufalis P, Chen CY, et al: Heritability of refractive error and ocular biometrics: the Genes in Myopia (GEM) twin study. Invest Ophthalmol Vis Sci 2006; 47: 4756-4761. (Pubitemid 46586372)
60. Young TL, Ronan SM, Drahozal LA, Wildenberg SC, Alvear AB, Oetting WS, et al: Evidence that a locus for familial high myopia maps to chromosome 18p. Am J Hum Gen 1998; 63: 109-119. (Pubitemid 30428325)
61. Nakanishi H, Yamada R, Gotoh N, Hayashi H, Yamashiro K, Shimada N, et al: A genome-wide association analysis identified a novel susceptible locus for pathological myopia at 11q24.1. PLoS Genet 2009; 5:e1000660.
62. Andrew T, Maniatis N, Carbonaro F, Liew SH, Lau W, Spector TD, et al: Identification and replication of three novel myopia common susceptibility gene loci on chromosome 3q26 using linkage and linkage disequilibrium mapping. PLoS Genet 2008; 4:e1000220.
63. Li Y, Vinckenbosch N, Tian G, Huerta-Sanchez E, Jiang T, Jiang H, et al: Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet 2010; 42: 969-972.
64. Martin NG, Martin PG: The inheritance of scholastic abilities in a sample of twins. I. Ascertainments of the sample and diagnosis of zygosity. Ann Hum Genet 1975; 39: 213-218.
65. Schwartz M, Haim M, Skarsholm D: Xlinked myopia: Bornholm eye disease. Linkage to DNA markers on the distal part of Xq. Clin Genet 1990; 38: 281-286. (Pubitemid 20340850)
66. Paluru PC, Nallasamy S, Devoto M, Rappaport EF, Young TL: Identification of a novel locus on 2q for autosomal dominant highgrade myopia. Invest Ophthalmol Vis Sci 2005; 46: 2300-2307. (Pubitemid 43119472)
67. Zhang Q, Guo X, Xiao X, Jia X, Li S, Hejtmancik JF: A new locus for autosomal dominant high myopia maps to 4q22-q27 between D4S1578 and D4S1612. Mol Vision 2005; 11: 554-560. (Pubitemid 41410221)
68. Naiglin L, Gazagne C, Dallongeville F, Thalamas C, Idder A, Rascol O, et al: A genome wide scan for familial high myopia suggests a novel locus on chromosome 7q36. J Med Genet 2002; 39: 118-124. (Pubitemid 34146381)
69. Zhu G, Hewitt AW, Ruddle JB, Kearns LS, Brown SA, Mackinnon JR, et al: Genetic dissection of myopia: evidence for linkage of ocular axial length to chromosome 5q. Ophthalmology 2008; 115: 1053-1057.
70. Stambolian D, Ibay G, Reider L, Dana D, Moy C, Schlifka M, et al: Genomewide linkage scan for myopia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 22q12. Am J Hum Genet 2004; 75: 448-459. (Pubitemid 39095820)
71. Hammond CJ, Andrew T, Mak YT, Spector TD: A susceptibility locus for myopia in the normal population is linked to the PAX6 gene region on chromosome 11: a genomewide scan of dizygotic twins. Am J Hum Genet 2004; 75: 294-304. (Pubitemid 38943872)
72. Paluru P, Ronan SM, Heon E, Devoto M, Wildenberg SC, Scavello G, et al: New locus for autosomal dominant high myopia maps to the long arm of chromosome 17. Invest Ophthalmol Vis Sci 2003; 44: 1830-1836. (Pubitemid 36520269)
73. Young TL, Ronan SM, Alvear AB, Wildenberg SC, Oetting WS, Atwood LD, et al: A second locus for familial high myopia maps to chromosome 12q. Am J Hum Genet 1998; 63: 1419-1424. (Pubitemid 30418539)
74. Ibay G, Doan B, Reider L, Dana D, Schlifka M, Hu H, et al: Candidate high myopia loci on chromosomes 18p and 12q do not play a major role in susceptibility to common myopia. BMC Med Genet 2004; 5: 20.
75. Mutti DO, Semina E, Marazita M, Cooper M, Murray JC, Zadnik K: Genetic loci for pathological myopia are not associated with juvenile myopia. Am J Med Genet 2002; 112: 355-360.
76. Lam DS, Lee WS, Leung YF, Tam PO, Fan DS, Fan BJ, et al: TGF beta-induced factor: a candidate gene for high myopia. Invest Ophthalmol Vis Sci 2003; 44: 1012-1015. (Pubitemid 36297814)
77. Scavello GS, Paluru PC, Ganter WR, Young TL: Sequence variants in the transforming growth beta-induced factor (TGIF) gene are not associated with high myopia. Invest Ophthalmol Vis Sci 2004; 45: 2091-2097. (Pubitemid 38902575)
78. Wang IJ, Chiang TH, Shih YF, Hsiao CK, Lu SC, Hou YC, et al: The association of single nucleotide polymorphisms in the 5, regulatory region of the lumican gene with susceptibility to high myopia in Taiwan. Mol Vision 2006; 12: 852-857. (Pubitemid 44178167)
79. Majava M, Bishop PN, Hagg P, Scott PG, Rice A, Inglehearn C, et al: Novel mutations in the small leucine-rich repeat protein/proteoglycan (SLRP) genes in high myopia. Hum Mutat 2007; 28: 336-344. (Pubitemid 46542920)
80. Wojciechowski R: Nature and nurture: the complex genetics of myopia and refractive error. Clin Genet 2011; 79: 301-320.
81. Jacobi FK, Pusch CM: A decade in search of myopia genes. Front Biosci 2010; 15: 359-372.
82. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, et al: Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003; 87: 570-573. (Pubitemid 36535327)
83. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ: Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103: 1241-1244. (Pubitemid 26282507)
84. Nagaoka N, Shimada N, Hayashi W, Hayashi K, Moriyama M, Yoshida T, et al: Characteristics of periconus choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2011; 152: 420-427.
85. Hayashi K, Ohno-Matsui K, Yoshida T, Kobayashi K, Kojima A, Shimada N, et al: Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005; 243: 13-19.
86. Shimada N, Ohno-Matsui K, Yoshida T, Futagami S, Tokoro T, Mochizuki M: Development of macular hole and macular retinoschisis in eyes with myopic choroidal neovascularization. Am J Ophthalmol 2008; 145: 155-161.
87. Kobayashi T, Ikuno Y: Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol 2010; 94: 611-615.
88. Kobayashi K, Mandai M, Suzuma I, Kobayashi H, Okinami S: Expression of estrogen receptor in the choroidal neovascular membranes in highly myopic eyes. Retina 2002; 22: 418-422. (Pubitemid 35025516)
89. Curtin BJ: Anterior chamber anomalies and pathologic myopia. Acta Ophthalmol Suppl 1988; 185: 111-113.
90. Ikuno Y, Jo Y, Hamasaki T, Tano Y: Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci 2010; 51: 3721-3725.
91. Ikuno Y, Sayanagi K, Soga K, Sawa M, Gomi F, Tsujikawa M, et al: Lacquer crack formation and choroidal neovascularization in pathologic myopia. Retina 2008; 28: 1124-1131.
92. Shiose S, Hata Y, Noda Y, Sassa Y, Takeda A, Yoshikawa H, et al: Fibrinogen stimulates in vitro angiogenesis by choroidal endothelial cells via autocrine VEGF. Graefes Arch Clin Exp Ophthalmol 2004; 242: 777-783. (Pubitemid 39386379)
93. Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H: Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 1999; 40: 3287-3291.
94. Duke-Elder S: Pathological refractive errors: ophthalmic optics and refraction; in Duke-Elder S (ed): System of Ophthalmology. St Louis, Mosby, 1970, pp 297-373.
95. Ohno H: Electron microscopic studies of myopic retinochoroidal atrophies. 1. Choroidal changes (in Japanese). Folia Ophthalmol Jpn1983; 43: 1244-1253.
96. Report of research committee on chorioretinal degenerations (1978).
97. Tokoro T: Diffuse chorioretinal atrophy; in Tokoro T (ed): Atlas of Posterior Fundus Changes in Pathologic Myopia. Tokyo, Springer, 1998, pp 7-14.
98. Quaranta M, Arnold J, Coscas G, Francais C, Quentel G, Kuhn D, et al: Indocyanine green angiographic features of pathologic myopia. Am J Ophthalmol 1996; 122: 663-671. (Pubitemid 26371374)
99. Akyol N, Kukner AS, Ozdemir T, Esmerligil S: Choroidal and retinal blood flow changes in degenerative myopia. Can J Ophthalmol 1996; 31: 113-119. (Pubitemid 26171895)
100. Pauleikhoff D, Spital G, Radermacher M, Brumm GA, Lommatzsch A, Bird AC: A fluorescein and indocyanine green angiographic study of choriocapillaris in age-related macular disease. Arch Ophthalmol 1999; 117: 1353-1358. (Pubitemid 30029345)
101. Sasahara M, Tsujikawa A, Musashi K, Gotoh N, Otani A, Mandai M, et al: Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol 2006; 142: 601-607.
102. Iida T, Kishi S, Hagimura N, Shimizu K: Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina 1999; 19: 508-512. (Pubitemid 30387484)
103. Brancato R, Trabucchi G, Introini U, Avanza P, Pece A: Indocyanine green angiography (ICGA) in pathological myopia. Eur J Ophthalmol 1996; 6: 39-43. (Pubitemid 26143190)
104. Ohno-Matsui K, Morishima N, Ito M, et al: Indocyanine-green angiographic findings of lacquer cracks in pathologic myopia. Jpn J Ophthalmol 1998; 42: 293-299. (Pubitemid 28431804)
105. Axer-Siegel R, Cotlear D, Priel E, Rosen blatt I, Snir M, Weinberger D: Indocyanine green angiography in high myopia. Ophthalmic Surg Lasers Imaging 2004; 35: 139-145. (Pubitemid 38338446)
106. Liu DT, Lam DS, Chan WM: Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment. Am J Ophthalmol 2004; 137: 383, author reply 6.
107. Baba T, Ohno-Matsui K, Yoshida T, Yasuzumi K, Futagami S, Tokoro T, et al: Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol Scand 2002; 80: 82-87. (Pubitemid 34506348)
108. Sayanagi K, Ikuno Y, Soga K, Tano Y: Photoreceptor inner and outer segment defects in myopic foveoschisis. Am J Ophthalmol 2008; 145: 902-908.
109. Hirata A, Negi A: Morphological changes of choriocapillaris in experimentally induced chick myopia. Graefes Arch Clin Exp Ophthalmol 1998; 236: 132-137. (Pubitemid 28080514)
110. Moriyama M, Ohno-Matsui K, Futagami S, Yoshida T, Hayashi K, Shimada N, et al: Morphology and long-term changes of choroidal vascular structure in highly myopic eyes with and without posterior staphyloma. Ophthalmology 2007; 114: 1755-1762.
111. Ikuno Y, Tano Y: Retinal and choroidal biometry in highly myopic eyes with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2009; 50: 3876-3880.
112. Vance SK, Khan S, Klancnik JM, Freund KB: Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis. Retina 2011; 31: 717-723.
113. Spaide R, Koizumi H, Pozonni M: Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 146: 496-500.
114. Margolis R, Spaide RF: A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009; 147: 811-815.
115. Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF: Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol 2009; 148: 445-450.
116. Shimada N, Ohno-Matsui K, Baba T, Futagami S, Tokoro T, Mochizuki M: Natural course of macular retinoschisis in highly myopic eyes without macular hole or retinal detachment. Am J Ophthalmol 2006; 142: 497-500. (Pubitemid 44691736)
117. Virgili G, Menchini F: Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005; 4:CD004765.
118. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al: Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report No 3. Ophthalmology 2003; 110: 667-673. (Pubitemid 36520061)
119. Baba T, Kubota-Taniai M, Kitahashi M, Okada K, Mitamura Y, Yamamoto S: Twoyear comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010; 94: 864-870.
120. Pece A, Isola V, Vitale L: Management of choroidal neovascularization in myopic choroidal neovascularization. Expert Rev Ophthalmol 2008; 3: 311-323.
121. Jalkh AE, Weiter JJ, Trempe CL, Pruett RC, Schepens CL: Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg 1987; 18: 721-725.
122. Steidl SM, Pruett RC: Macular complications associated with posterior staphyloma. Am J Ophthalmol 1997; 123: 181-187. (Pubitemid 27066773)
123. Pece A, Brancato R, Avanza P, Camesasca F, Galli L: Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol 1994; 18: 339-344.
124. Oshima Y, Harino S, Tano Y: Scanning laser ophthalmoscope microperimetric assessment in patients with successful laser treatment for juxtafoveal choroidal neovascularization. Retina 1998; 18: 109-117. (Pubitemid 28182774)
125. Ruiz-Moreno JM, Montero JA: Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 2002; 12: 117-122. (Pubitemid 34587109)
126. Brancato R, Pece A, Avanza P, Radrizzani E: Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990; 10: 239-243.
127. Bandello F, Lanzetta P, Battaglia Parodi M, Roman-Pognuz D, Saviano S, Ravalico G: Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2003; 241: 567-570. (Pubitemid 36975055)
128. Johnson DA, Yannuzzi LA, Shakin JL, Lightman DA: Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 1998; 18: 118-124. (Pubitemid 28182775)
129. Ozdek S, Hondur A, Gurelik G, Hasanreisoglu B: Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV. Int Ophthalmol 2005; 26: 127-133. (Pubitemid 46371502)
130. Wu PC, Chen YJ, Chen CH, Chen YH, Kao ML, Shin SJ, et al: Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: one-and two-year follow up. Clin Exp Ophthalmol 2008; 36: 443-448.
131. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS: Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994; 101: 1384-1396. (Pubitemid 24319287)
132. Bottoni F, Perego E, Airaghi P, Cigada M, Ortolina S, Carlevaro G, et al: Surgical removal of subfoveal choroidal neovascular membranes in high myopia. Graefes Arch Clin Exp Ophthalmol 1999; 237: 573-582. (Pubitemid 29294943)
133. Uemura A, Thomas MA: Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 2000; 118: 344-350. (Pubitemid 30152374)
134. Ruiz-Moreno JM, de la Vega C: Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 2001; 85: 1041-1043. (Pubitemid 32835386)
135. Fujikado T, Ohji M, Saito Y, Hayashi A, Tano Y: Visual function after foveal translocation with scleral shortening in patients with myopic neovascular maculopathy. Am J Ophthalmol 1998; 125: 647-656. (Pubitemid 28265513)
136. Glacet-Bernard A, Simon P, Hamelin N, Coscas G, Soubrane G: Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am J Ophthalmol 2001; 131: 78-89. (Pubitemid 32037011)
137. Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G: Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs. surgical removal. Am J Ophthalmol 2002; 133: 530-536. (Pubitemid 34258062)
138. Fujikado T, Ohji M, Kusaka S, Hayashi A, Kamei M, Okada AA, et al: Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy. Am J Ophthalmol 2001; 131: 101-110. (Pubitemid 32037013)
139. Yamada Y, Miyamura N, Suzuma K, Kitaoka T: Long-term follow-up of full macular translocation for choroidal neovascularization. Am J Ophthalmol 2010; 149: 453-457 e1.
140. Glacet-Bernard A, Benyelles N, Dumas S, Haddad WM, Voigt M, Razavi S, et al: Photodynamic therapy vs. limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol 2007; 143: 68-76.
141. Verteporfin in Photodynamic Therapy Study G: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report No 1. Ophthalmology 2001; 108: 841-852.
142. Ergun E, Heinzl H, Stur M: Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004; 138: 434-438. (Pubitemid 39208575)
143. Campa C, Harding SP: Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010; 149: 1014-1015, author reply 5-6.
144. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A: Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 2005; 140: 416-425.
145. Lam DS, Chan WM, Liu DT, Fan DS, Lai WW, Chong KK: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1-and 2-year follow-up. Br J Ophthalmol 2004; 88: 1315-1319. (Pubitemid 39312979)
146. Pece A, Isola V, Vadala M, Matranga D: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina 2006; 26: 746-751. (Pubitemid 44386095)
147. Pece A, Vadala M, Isola V, Matranga D: Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study. Am J Ophthalmol 2007; 143: 449-454.
148. Ruiz-Moreno JM, Amat P, Montero JA, Lugo F: Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 2008; 92: 792-794. (Pubitemid 351839570)
149. Virgili G, Varano M, Giacomelli G, Arena MC, Tedeschi M, Pascarella A, et al: Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia. Am J Ophthalmol 2007; 143: 77-82.
150. Chan WM, Lai TY, Tano Y, Liu DT, Li KK, Lam DS: Photodynamic therapy in macular diseases of Asian populations: when East meets West. Jpn J Ophthalmology 2006; 50: 161-169.
151. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 174-179. (Pubitemid 46202864)
152. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hara W, et al: Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 2008; 145: 518-526.
153. Bandello F, Blinder K, Bressler NM, Brown AL, Miller JW, Potter MJ, et al: Verteporfin in photodynamic therapy: report No 5. Ophthalmology 2004; 111: 2144.
154. Hussain N, Khanna R, Das T, Narayanan R, Sunday OT, Bansal AG, et al: Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes. Indian J Ophthalmol 2008; 56: 465-468.
155. Ikuno Y, Nagai Y, Matsuda S, Arisawa A, Sho K, Oshita T, et al: Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010; 149: 140-146.
156. Schnurrbusch UE, Jochmann C, Wiedemann P, Wolf S: Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2005; 243: 829-833. (Pubitemid 41300427)
157. Coutinho AM, Silva RM, Nunes SG, Cachulo ML, Figueira JP, Murta JN: Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up. Retina 2011; 31: 1089-1094.
158. Lam DS, Liu DT, Fan DS, Lai WW, So SF, Chan WM: Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye 2005; 19: 834-840. (Pubitemid 41195134)
159. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelveweek results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047. (Pubitemid 40797459)
160. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA: Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005; 89: 1368-1370. (Pubitemid 41638883)
161. Manzano RP, Peyman GA, Khan P, Kivilcim M: Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26: 257-261. (Pubitemid 44318176)
162. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS: Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007; 91: 157-160. (Pubitemid 46202862)
163. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, et al: Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165. (Pubitemid 46202863)
164. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr: Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006; 26: 960-963. (Pubitemid 44547453)
165. Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, et al: Twelvemonth outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010; 30: 1609-1615.
166. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al: Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009; 147: 94-100.
167. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, et al: Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye 2009; 23: 334-338.
168. Chan WM, Lai TY, Liu DT, Lam DS: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009; 93: 150-154.
169. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB: Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147: 84-93.
170. Wu PC, Chen YJ: Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009; 23: 2042-2045.
171. Ruiz-Moreno JM, Montero JA: Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefe's Arch Clin Exp Ophthalmol 2010; 248: 937-941.
172. Voykov B, Gelisken F, Inhoffen W, Voelker M, Bartz-Schmidt KU, Ziemssen F: Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefe's Arch Clin Exp Ophthalmol 2010; 248: 543-550.
173. Nakanishi H, Tsujikawa A, Yodoi Y, Ojima Y, Otani A, Tamura H, et al: Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye 2011; 25: 375-381.
174. Gharbiya M, Allievi F, Conflitti S, Esposito M, Scavella V, Moramarco A, et al: Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter 2010; 161:e87-e93.
175. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S: Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009; 93: 448-451.
176. Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, et al: Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol 2009; 148: 396-408.
177. Yodoi Y, Tsujikawa A, Nakanishi H, Otani A, Tamura H, Ojima Y, et al: Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2009; 147: 816-824, 24 e1.
178. Scupola A, Tiberti AC, Sasso P, Savastano MC, Mastrocola A, Marangoni D, et al: Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results. Retina 2010; 30: 739-747.
179. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosa A, et al: Shortterm efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008; 28: 1117-1123.
180. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A, et al: Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27: 707-712. (Pubitemid 47051766)
181. Chan WM, Lai TY, Liu DT, Lam DS: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007; 114: 2190-2196.
182. Lai TY, Chan WM, Liu DT, Lam DS: Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29: 750-756.
183. Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, et al: Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010; 30: 407-412.
184. Mones JM, Amselem L, Serrano A, Garcia M, Hijano M: Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 2009; 23: 1275-1280, quiz 81.
185. Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, et al: Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010; 30: 399-406.
186. Calvo-Gonzalez C, Reche-Frutos J, Donate J, Fernandez-Perez C, Garcia-Feijoo J: Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment. Am J Ophthalmol 2011; 151: 529-534.
187. Vadala M, Pece A, Cipolla S, Monteleone C, Fasolino G, Casuccio A, et al: Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study. Br J Ophthalmol 2011; 95: 657-661.
188. Varano M, Tedeschi M, Oddone F, Perillo L, Coppe AM, Parravano M: Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. Retina 2010; 30: 413-417.
189. Franqueira N, Cachulo ML, Pires I, Fonseca P, Marques I, Figueira J, et al: Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 2012; 227: 39-44.
190. Soubrane G, Pison J, Bornert P, Perrenoud F, Coscas G: Subretinal neovessels in degenerative myopia: results of photocoagulation. Bull Soc Ophtalmol France 1986; 86: 269-272.
191. Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F: Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128: 437-442.
192. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, et al: Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-a randomized controlled trial. Am J Ophthalmol 2010; 149: 458-464 e1.
193. Yoon JU, Byun YJ, Koh HJ: Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010; 30: 418-424.
194. Kojima A, Ohno-Matsui K, Teramukai S, Ishihara Y, Shimada N, Yoshida T, et al: Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefe's Arch Clin Exp Ophthalmol 2006; 244: 1474-1479. (Pubitemid 44741259)
195. Axer-Siegel R, Ehrlich R, Weinberger D, Rosenblatt I, Shani L, Yassur Y, et al: Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004; 138: 602-607. (Pubitemid 39420488)
196. Arias L, Planas N, Prades S, Caminal JM, Rubio M, Pujol O, et al: Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008; 92: 1035-1039.
197. Ng DS, Kwok A, Chan CW: Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clin Exp Ophthalmol 2012; 40:e98-e110.
198. Grossniklaus HE, Gass JD: Clinicopathologic correlations of surgically excised type and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998; 126: 59-69. (Pubitemid 28341219)